Related Experiment Video
Updated: Nov 11, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Why isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different
1Cancer Center - Froedtert Hospital, Medical College of Wisconsin, 9200 Wisconsin Ave, Milwaukee, WI, 53226, USA.
Abstract:
Relapsed refractory acute myeloid leukemia (R/R AML) has a poor prognosis. While the heterogeneity and diversity of R/R AML pose hurdles towards defining a standard of care, there have been various advances over the years. These, however, have added to the complexity of decision-making for R/R AML. This review has summarized evidence that will provide insights into factors that influence treatment choices in R/R AML and determine whether ongoing clinical trials can aid in identifying a standard approach for different sub-groups of patients.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Factors Affecting Drug Response: Overview
Treatment Resistant Cancers
Therapeutic Drug Monitoring: Affecting Factors
Differentiation of Common Myeloid Progenitor Cells
Lineage Commitment